Sapkota Y, Qin N, Ehrhardt MJ, et al. - To determine genetic variants related to therapy-associated cardiomyopathy in childhood cancer survivors of African ancestry, researchers performed this inquiry. They performed a comparison between childhood cancer survivors of African ancestry exposed to cardiotoxic therapies (anthracyclines and/or heart radiation) (n = 246) vs cardiotoxic-exposed survivors of European ancestry (n = 1,645) in the St. Jude Lifetime Cohort. Experts found 1.53- and 2.47-fold risks of CTCAE grade 2-4 and grade 3-4 cardiomyopathy among survivors of African ancestry vs survivors of European ancestry. Among 246 survivors of African ancestry, there was a significant link of a novel locus at 1p13.2 with ejection fraction (EF) [rs6689879*C: EF reduction = 4.2%; P = 2.8×10-8], which was successfully replicated in 1,645 survivors of European ancestry but with reduced magnitude (EF reduction = 0.4%; P = 0.042). Hypomethylation of PHTF1 promoter region was seen in survivors of African ancestry with rs6689879*C and CTCAE grade 2-4 cardiomyopathy. These data carry potential implications for long-term cardiac surveillance as well as up-front cancer care for patients of African ancestry.